论文部分内容阅读
目的评估促红细胞生成素治疗老年脑梗死的临床疗效和安全性。方法选取2015年10月-2016年10月来医院接受治疗的脑梗死患者92例作为研究对象,依照随机、单盲法分成治疗组和常规组,每组46例,其中常规组患者施以常规治疗,治疗组患者在上述基础上使用促红细胞生成素治疗,对2组患者治疗效果进行评估,并对治疗前后2组患者脑梗死体积、神经功能缺损程度及日常生活情况进行评估,并对比2组血清C反应蛋白浓度,最后评估2组治疗期间发生的不良反应情况。结果治疗组患者的总有效率93.5%明显高于常规组的78.3%,差异有统计学意义(χ2=4.390,P<0.05)。治疗前2组脑梗死体积对比差异无统计学意义(P>0.05),治疗后2组患者的梗死体积均小于治疗前,且治疗组治疗后梗死体积明显少于常规组,差异均有统计学意义(P<0.05)。治疗前2组患者神经功能缺损、日常生活情况及C反应蛋白浓度比较差异均无统计学意义(P>0.05)。治疗后2组患者日常生活情况评分明显高于治疗前,神经功能缺损评分与C反应蛋白浓度明显低于治疗前,且治疗组变化幅度大于常规组,差异均有统计学意义(P<0.05)。治疗组患者治疗后不良反应发生率为30.4%明显低于常规组的52.2%,差异有统计学意义(χ2=4.483,P<0.05)。结论促红细胞生成素治疗老年脑梗死的临床疗效显著,能很好地改善老年患者其神经功能,具有较高的安全性。
Objective To evaluate the clinical efficacy and safety of erythropoietin in the treatment of senile cerebral infarction. Methods Ninety-two patients with cerebral infarction who were treated in the hospital from October 2015 to October 2016 were divided into treatment group and conventional group according to a randomized, single-blind method, with 46 patients in each group. The patients in the conventional group were given conventional Treatment, treatment group patients on the basis of the above-mentioned use of erythropoietin treatment, the treatment of two groups were evaluated, and before and after treatment in two groups of patients with cerebral infarction volume, neurological deficit and daily living conditions were evaluated and compared 2 Group serum C-reactive protein concentration, the final assessment of adverse reactions occurred during the two groups during treatment. Results The total effective rate was 93.5% in the treatment group was significantly higher than 78.3% of the conventional group, the difference was statistically significant (χ2 = 4.390, P <0.05). There was no significant difference in the volume of cerebral infarction between the two groups before treatment (P> 0.05). The volume of infarction in both groups after treatment was less than that before treatment, and the volume of infarction in the treatment group was significantly less than that of the conventional group Significance (P <0.05). There was no significant difference in neurological deficit, daily life and C-reactive protein between the two groups before treatment (P> 0.05). After treatment, the daily life scores of the two groups of patients were significantly higher than those before treatment, the neurological deficit score and C-reactive protein level were significantly lower than those before treatment, and the changes in the treatment group were greater than those in the conventional group (P <0.05) . The incidence of adverse reactions in the treatment group was significantly lower than that in the control group (30.4% vs 52.2%, χ2 = 4.483, P <0.05). Conclusion Erythropoietin has a significant clinical effect in the treatment of senile cerebral infarction, which can improve the neurological function of senile patients well and has higher safety.